Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.

[1]  Ming Yi,et al.  Non-B DB v2.0: a database of predicted non-B DNA-forming motifs and its associated tools , 2012, Nucleic Acids Res..

[2]  V. Chasnyk,et al.  Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis , 2013, Journal of Inherited Metabolic Disease.

[3]  E. Bertini,et al.  Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. , 2012, American journal of human genetics.

[4]  F. Jasmi.  A novel mutation in an atypical presentation of the rare infantile Farber disease , 2012, Brain and Development.

[5]  N. Kaya,et al.  Novel V97G ASAH1 mutation found in Farber disease patients: Unique appearance of the disease with an intermediate severity, and marked early involvement of central and peripheral nervous system , 2012, Brain and Development.

[6]  M. Bashyam,et al.  Novel biochemical abnormalities and genotype in Farber disease. , 2012, Indian pediatrics.

[7]  T. Levade,et al.  Farber lipogranulomatosis type 1--late presentation and early death in a Croatian boy with a novel homozygous ASAH1 mutation. , 2011, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[8]  T. Manabe,et al.  Aberrant regulation of alternative pre-mRNA splicing in schizophrenia , 2010, Neurochemistry International.

[9]  R. Wells,et al.  Non‐B DNA conformations as determinants of mutagenesis and human disease , 2009, Molecular carcinogenesis.

[10]  C. Béroud,et al.  Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.

[11]  Jae-Ho Park,et al.  Autoproteolytic Cleavage and Activation of Human Acid Ceramidase* , 2008, Journal of Biological Chemistry.

[12]  D. Cane,et al.  The nonsense-mediated decay RNA surveillance pathway. , 2007, Annual review of biochemistry.

[13]  M. Bashyam,et al.  Farber lipogranulomatosis: clinical and molecular genetic analysis reveals a novel mutation in an Indian family , 2006, Journal of Human Genetics.

[14]  M. Batzer,et al.  Retrotransposable elements and human disease. , 2006, Genome dynamics.

[15]  A. Feigenbaum,et al.  Bone marrow involvement and obstructive jaundice in Farber lipogranulomatosis: clinical and autopsy report of a new case , 1996, Journal of Inherited Metabolic Disease.

[16]  K. Inui,et al.  Mutation analysis of the acid ceramidase gene in Japanese patients with Farber disease , 2002, Journal of Inherited Metabolic Disease.

[17]  Christopher B. Burge,et al.  Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals , 2003, RECOMB '03.

[18]  F. Lang,et al.  Human Acid Ceramidase , 2001, The Journal of Biological Chemistry.

[19]  T. Linke,et al.  Molecular analysis of acid ceramidase deficiency in patients with Farber disease , 2001, Human mutation.

[20]  H. Moser,et al.  Human acid ceramidase gene: novel mutations in Farber disease. , 2000, Molecular genetics and metabolism.

[21]  D. Adler,et al.  The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. , 1999, Genomics.

[22]  J. Medin,et al.  Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells. , 1999, Human gene therapy.

[23]  E. Kattner,et al.  Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease , 1997, European Journal of Pediatrics.

[24]  R. Desnick,et al.  Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase , 1996, The Journal of Biological Chemistry.

[25]  A. Schäfer,et al.  Disseminierte Lipogranulomatose (M. Farber) mit Hydrops fetalis , 1996, Der Pathologe.

[26]  R. Salvayre,et al.  A simple method for screening for Farber disease on cultured skin fibroblasts. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[27]  R. Desnick,et al.  Purification, characterization, and biosynthesis of human acid ceramidase , 1995, The Journal of Biological Chemistry.

[28]  D. Eide,et al.  The FET3 Gene Product Required for High Affinity Iron Transport in Yeast Is a Cell Surface Ferroxidase (*) , 1995, The Journal of Biological Chemistry.

[29]  R. Bell,et al.  Changes in bioactive lipids, alkylacylglycerol and ceramide, occur in HIV-infected cells. , 1992, Biochemical and biophysical research communications.

[30]  J. Preiss,et al.  Quantitative measurement of sn-1,2-diacylglycerols. , 1987, Methods in enzymology.

[31]  H. Moser,et al.  Farber disease: pathologic diagnosis in sibs with phenotypic variability. , 1987, American journal of medical genetics. Supplement.

[32]  H. Moser,et al.  Phenotypic variability in siblings with Farber disease. , 1984, The Journal of pediatrics.

[33]  R. Cortese,et al.  Characterization of an imidazolepyruvic acid reducing system from Escherichiacoli B , 1968 .

[34]  B. Ames.  ASSAY OF INORGANIC PHOSPHATE, TOTAL PHOSPHATE AND PHOSPHATASE , 1966 .

[35]  S. Gatt.  ENZYMIC HYDROLYSIS AND SYNTHESIS OF CERAMIDES. , 1963, The Journal of biological chemistry.